NEW YORK (GenomeWeb News) – Cardiovascular genomics diagnostics company CardioDx today announced the completion of a $58 million equity financing round.

The company, which recently received Medicare coverage for its coronary artery disease test called Corus CAD, will use the funding to support commercialization of the gene expression test and to develop other genomics diagnostics for cardiovascular disease, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.